We are thrilled to enter into a definitive agreement with Kalaris and see an opportunity to work with the Kalaris team to bring their innovative investigational anti-VEGF treatment, TH103, to help patients suffering from vision-impairing retinal diseases. We look forward to working with the veteran Kalaris team in the coming months.? ? Read the full press release here: https://lnkd.in/eEPJUvhU
AlloVir
生物技术研究
Waltham，MA 9,069 位关注者
A global leader in allogeneic, off-the-shelf, multi-virus specific T- cell immunotherapies
关于我们
AlloVir, formerly ViraCyte, was founded in 2013 and is the leader in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The company’s technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viral pathogens for immunocompromised patients under viral attack. AlloVir’s technology and manufacturing process enables the potential for the treatment and/or prevention of up to six devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio.
- 网站
-
https://www.allovir.com
AlloVir的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Waltham，MA
- 类型
- 上市公司
- 领域
- Cell Therapy、Infectious disease、Therapeutic developer和Biotechnology